Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction cancer: Phase III KEYNOTE-859 study
Presenter: Sun Young Rha, Republic of Korea; Discussant: Elizabeth Smyth, UK; AACR expert commentary: Brian S. Henick, USA